D.-W. Kim

2.1k total citations · 2 hit papers
53 papers, 1.2k citations indexed

About

D.-W. Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, D.-W. Kim has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in D.-W. Kim's work include Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (17 papers) and Lung Cancer Research Studies (14 papers). D.-W. Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (17 papers) and Lung Cancer Research Studies (14 papers). D.-W. Kim collaborates with scholars based in South Korea, United States and Spain. D.-W. Kim's co-authors include Tony Mok, S.-H.I. Ou, D. Ross Camidge, Shirish M. Gadgeel, Vlatka Smoljanović, Solange Peters, Rafał Dziadziuszko, Magalie Hilton, M. Pérol and Walter Bordogna and has published in prestigious journals such as Electrochimica Acta, Annals of Oncology and European Journal of Cancer.

In The Last Decade

D.-W. Kim

52 papers receiving 1.2k citations

Hit Papers

Updated overall survival and final progression-free survi... 2020 2026 2022 2024 2020 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
    2020 414 citations Tony Mok, D. Ross Camidge et al. Annals of Oncology profile →
  2. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.-W. Kim South Korea 15 844 775 232 202 162 53 1.2k
Joseph Fiore United States 12 1.5k 1.8× 1.0k 1.3× 125 0.5× 183 0.9× 340 2.1× 23 1.7k
Junjie Xi China 20 295 0.3× 428 0.6× 560 2.4× 297 1.5× 102 0.6× 66 1.1k
Shunliang Gao China 16 552 0.7× 279 0.4× 212 0.9× 238 1.2× 32 0.2× 60 1.1k
Yunlang She China 16 152 0.2× 261 0.3× 301 1.3× 190 0.9× 38 0.2× 34 949
Julie E. Stein United States 12 658 0.8× 281 0.4× 211 0.9× 151 0.7× 275 1.7× 24 1.0k
Akira Fukunaga Japan 10 635 0.8× 98 0.1× 217 0.9× 124 0.6× 385 2.4× 30 975
Gabriele Gamerith Austria 18 507 0.6× 200 0.3× 233 1.0× 193 1.0× 178 1.1× 44 914
Zi-Qi Zhou China 14 216 0.3× 88 0.1× 168 0.7× 120 0.6× 150 0.9× 16 515
Ritesh Rathore United States 15 837 1.0× 242 0.3× 217 0.9× 113 0.6× 239 1.5× 44 1.0k
Lindsey Rolfe United States 12 622 0.7× 199 0.3× 374 1.6× 174 0.9× 78 0.5× 30 856

Countries citing papers authored by D.-W. Kim

Since Specialization
Citations

This map shows the geographic impact of D.-W. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.-W. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.-W. Kim more than expected).

Fields of papers citing papers by D.-W. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.-W. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.-W. Kim. The network helps show where D.-W. Kim may publish in the future.

Co-authorship network of co-authors of D.-W. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of D.-W. Kim. A scholar is included among the top collaborators of D.-W. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.-W. Kim. D.-W. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tan, Aaron C., D.-W. Kim, Gwo Fuang Ho, et al.. (2023). P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study. Journal of Thoracic Oncology. 18(11). S352–S353.
2.
Jänne, Pasi A., Yasushi Goto, Toshio Kubo, et al.. (2023). MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02. Journal of Thoracic Oncology. 18(11). S148–S148. 2 indexed citations
3.
Kim, D.-W., et al.. (2022). EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial. Journal of Thoracic Oncology. 17(9). S408–S409. 1 indexed citations
4.
Gainor, Justin F., Giuseppe Curigliano, D.-W. Kim, et al.. (2021). MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 16(1). S31–S32. 2 indexed citations
5.
Niu, Jiaxin, Corinne Maurice‐Dror, D.H. Lee, et al.. (2021). First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Annals of Oncology. 33(2). 169–180. 196 indexed citations breakdown →
6.
7.
Herbst, Roy S., Edward B. Garon, D.-W. Kim, et al.. (2018). Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Annals of Oncology. 29. viii749–viii749. 17 indexed citations
8.
Tan, Daniel S.W., Lecia V. Sequist, Santiago Ponce Aix, et al.. (2018). Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii748–viii748. 4 indexed citations
9.
10.
Antonia, Scott, Julie R. Brahmer, Samir N. Khleif, et al.. (2016). Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi421–vi421. 32 indexed citations
11.
Ramalingam, Suresh S., Chee Khoon Lee, Takayasu Kurata, et al.. (2016). LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. Journal of Thoracic Oncology. 11(4). S152–S152. 51 indexed citations
12.
13.
Tan, Daniel Shao-Weng, D.-W. Kim, Enriqueta Felip, et al.. (2016). 178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC. Journal of Thoracic Oncology. 11(4). S134–S135. 2 indexed citations
14.
15.
16.
Jänne, Pasi A., Myung‐Ju Ahn, D.-W. Kim, et al.. (2015). A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc – Updated Progression Free Survival and Duration of Response Data. Annals of Oncology. 26. i57–i57. 15 indexed citations
17.
Soo, Ross A., D.-W. Kim, K. Park, et al.. (2015). 469P Highly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met+ NSCLC. Annals of Oncology. 26. ix125–ix125. 3 indexed citations
18.
Herbst, Roy S., D.-W. Kim, Enriqueta Felip, et al.. (2015). LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy. Annals of Oncology. 26. ix161–ix161. 1 indexed citations
19.
Kim, D.-W., Ranee Mehra, Daniel Shao-Weng Tan, et al.. (2015). Ceritinib Treatment of Patients (PTS) with Alk-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: Ascend-1 Trial Experience. Annals of Oncology. 26. i29–i29. 2 indexed citations
20.
Nokihara, Hiroshi, Vera Hirsh, Fiona Blackhall, et al.. (2013). Phase III Study of Crizotinib vs. Chemotherapy in Advanced ALK+ NSCLC: Patient-Reported Symptoms and Quality of Life. Annals of Oncology. 24. ix43–ix43. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph Fiore Breakdown of academic impact, for papers by Junjie Xi Breakdown of academic impact, for papers by Shunliang Gao Breakdown of academic impact, for papers by Yunlang She Breakdown of academic impact, for papers by Julie E. Stein Breakdown of academic impact, for papers by Akira Fukunaga Breakdown of academic impact, for papers by Gabriele Gamerith Breakdown of academic impact, for papers by Zi-Qi Zhou Breakdown of academic impact, for papers by Ritesh Rathore Breakdown of academic impact, for papers by Lindsey Rolfe
Rankless by CCL
2026